Information Journal Paper
APA:
Copy. (2017). Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. LANCET DIABETES ENDOCRINOLOGY, 5(11), 864-876. SID. https://sid.ir/paper/775949/en
Vancouver:
Copy. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. LANCET DIABETES ENDOCRINOLOGY[Internet]. 2017;5(11):864-876. Available from: https://sid.ir/paper/775949/en
IEEE:
Copy, “Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial,” LANCET DIABETES ENDOCRINOLOGY, vol. 5, no. 11, pp. 864–876, 2017, [Online]. Available: https://sid.ir/paper/775949/en